EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23
EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Change in Forecast/Half Year Results
Contact for investors and press Sebastian Frericks Head of Group Finance Investor Relations Tel.: +49 3641 220-116 E-Mail: [email protected]
End of Inside Information
19-Apr-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Carl Zeiss Meditec AG |
Göschwitzer Str. 51-52 | |
07745 Jena, Germany | |
Germany | |
Phone: | +49 (0)3641 220-0 |
Fax: | +49 (0)3641 220-112 |
E-mail: | [email protected] |
Internet: | www.zeiss.de/meditec-ag/ir |
ISIN: | DE0005313704 |
WKN: | 531370 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1610981 |
End of Announcement | EQS News Service |
|
1610981 19-Apr-2023 CET/CEST
Carl Zeiss Meditec AG Aktie
Gleichstand bei Carl Zeiss Meditec AG: Die Anzahl der Buy- und Sell-Einschätzungen ist gleich.
Die Community sieht für Carl Zeiss Meditec AG ein Kursziel von 122 €, was den aktuellen Kurs von 58.25 € weit übersteigt.